Leading pharmaceutical R&D projects by NPV 2026

Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars)

Projected most valuable R&D projects based on net present value 2026

Last update:

Jan 12, 2026

Author:

�ֲ��ýapp��°汾 Research Department

Region:

Worldwide

Survey time period:

From 06/01/2026 to 06/01/2026

As of January 2026, the leading pharmaceutical R&D project was Retatrutide by Eli Lily with a net present value of about billion U.S. dollars. Amycretin from Novo Nordisk followed as the second leading project with a net present value of approximately billion U.S. dollars.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�ֲ���ýapp���°汾

Leading pharmaceutical R&D projects based on net present value (NPV) as of January 2026 (in billion U.S. dollars)

Get in touch with us for additional information

�ֲ��ýapp��°汾